Patents by Inventor Harry G. Brittain

Harry G. Brittain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polymorphic Forms of Naltrexone
    Publication number: 20170209430
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Application
    Filed: December 16, 2016
    Publication date: July 27, 2017
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • AMORPHOUS ONAPRISTONE COMPOSITIONS AND METHODS OF MAKING THE SAME
    Publication number: 20170182065
    Abstract: Amorphous forms of onapristone and methods of making such amorphous forms are provided. Amorphous forms can be characterized by their X-ray powder diffraction patterns and other properties.
    Type: Application
    Filed: December 13, 2016
    Publication date: June 29, 2017
    Inventors: Harry G. Brittain, Stefan Proniuk
  • CHARACTERIZATION OF THE COCRYSTAL PRODUCTS FORMED BY METOPROLOL AND DABIGATRAN BASES WITH L-THEANINE
    Publication number: 20170143838
    Abstract: Cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.
    Type: Application
    Filed: October 3, 2016
    Publication date: May 25, 2017
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: HARRY G. BRITTAIN, Philip V. Felice
  • CHARACTERIZATION OF THE COCRYSTAL PRODUCTS FORMED BY METOPROLOL AND DABIGATRAN BASES WITH L-THEANINE
    Publication number: 20170143648
    Abstract: Methods of treating and preventing conditions by employing cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.
    Type: Application
    Filed: November 17, 2016
    Publication date: May 25, 2017
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • CHARACTERIZATION OF THE COCRYSTAL PRODUCTS FORMED BY METOPROLOL AND DABIGATRAN BASES WITH L-THEANINE
    Publication number: 20170144964
    Abstract: Methods of making cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.
    Type: Application
    Filed: November 17, 2016
    Publication date: May 25, 2017
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Platform drug delivery system utilizing crystal engineering and theanine dissolution
    Patent number: 9603939
    Abstract: A method of treating Hodgkin's disease in a subject. The method involves administering to the subject an effective amount of a water-soluble composition which includes a cocrystal composition containing doxorubicin and a theanine enantiomer.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: March 28, 2017
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Platform drug delivery system utilizing crystal engineering and theanine dissolution
    Patent number: 9603937
    Abstract: A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: March 28, 2017
    Assignee: Theaprin Pharmaceuticals Inc.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Platform drug delivery system utilizing crystal engineering and theanine dissolution
    Patent number: 9603938
    Abstract: A method of making a water-soluble doxorubicin-theanine cocrystal composition. The method includes the steps of providing a quantity of doxorubicin, adding a quantity of a theanine enantiomer to the quantity of doxorubicin to form a mixture of the quantity of doxorubicin and the enantiomer of theanine, wetting the mixture, and grinding the mixture for a length of time sufficient to produce a dried crystalline mass.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: March 28, 2017
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Polymorphic forms of naltrexone
    Patent number: 9556189
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: January 31, 2017
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • POLYMORPHIC FORMS OF NALTREXONE
    Publication number: 20160362415
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Application
    Filed: June 7, 2016
    Publication date: December 15, 2016
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • PLATFORM DRUG DELIVERY SYSTEM UTILIZING CRYSTAL ENGINEERING AND THEANINE DISSOLUTION
    Publication number: 20160263229
    Abstract: A method of making a water-soluble doxorubicin-theanine cocrystal composition. The method includes the steps of providing a quantity of doxorubicin, adding a quantity of a theanine enantiomer to the quantity of doxorubicin to form a mixture of the quantity of doxorubicin and the enantiomer of theanine, wetting the mixture, and grinding the mixture for a length of time sufficient to produce a dried crystalline mass.
    Type: Application
    Filed: March 24, 2016
    Publication date: September 15, 2016
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: HARRY G. BRITTAIN, Philip V. Felice
  • PLATFORM DRUG DELIVERY SYSTEM UTILIZING CRYSTAL ENGINEERING AND THEANINE DISSOLUTION
    Publication number: 20160263224
    Abstract: A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.
    Type: Application
    Filed: March 9, 2015
    Publication date: September 15, 2016
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • PLATFORM DRUG DELIVERY SYSTEM UTILIZING CRYSTAL ENGINEERING AND THEANINE DISSOLUTION
    Publication number: 20160263138
    Abstract: A method of treating Hodgkin's disease in a subject. The method involves administering to the subject an effective amount of a water-soluble composition which includes a cocrystal composition containing doxorubicin and a theanine enantiomer.
    Type: Application
    Filed: April 13, 2016
    Publication date: September 15, 2016
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: HARRY G. BRITTAIN, Philip V. Felice
  • Polymorphic forms of naltrexone
    Patent number: 9365580
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: June 14, 2016
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Polymorphic Forms of Naltrexone
    Publication number: 20160137657
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Application
    Filed: November 19, 2015
    Publication date: May 19, 2016
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine
    Patent number: 9289438
    Abstract: A method of treating high grade temperature using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: March 22, 2016
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine
    Patent number: 9289439
    Abstract: A method of reducing hepatocellular damage in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: March 22, 2016
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine
    Patent number: 9289440
    Abstract: A method of treating myocardial infarction in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: March 22, 2016
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Polymorphic forms of naltrexone
    Patent number: 9221830
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: December 29, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Polymorphic Forms Of Naltrexone
    Publication number: 20150218178
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Application
    Filed: February 3, 2015
    Publication date: August 6, 2015
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright